Collegium Pharmaceutical, Inc. $COLL Stock Holdings Increased by Quantinno Capital Management LP

Quantinno Capital Management LP grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 195.6% in the first quarter, HoldingsChannel reports. The fund owned 56,242 shares of the specialty pharmaceutical company’s stock after buying an additional 37,213 shares during the period. Quantinno Capital Management LP’s holdings in Collegium Pharmaceutical were worth $1,860,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of COLL. Group One Trading LLC bought a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its position in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 427 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on COLL. Needham & Company LLC reduced their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Wall Street Zen lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $52.60.

Collegium Pharmaceutical Stock Down 4.5%

NASDAQ COLL opened at $25.98 on Wednesday. The company has a market capitalization of $845.80 million, a P/E ratio of 20.95 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 12 month low of $25.90 and a 12 month high of $50.79. The company has a debt-to-equity ratio of 3.32, a current ratio of 1.03 and a quick ratio of 0.84. The company’s 50 day simple moving average is $34.60 and its 200 day simple moving average is $36.72.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to analysts’ expectations of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The firm’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.68 earnings per share. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.